Last reviewed · How we verify
Tofacitinib tablet
Tofacitinib inhibits Janus kinase (JAK) enzymes to suppress inflammatory cytokine signaling and reduce immune-mediated inflammation.
Tofacitinib inhibits Janus kinase (JAK) enzymes to suppress inflammatory cytokine signaling and reduce immune-mediated inflammation. Used for Rheumatoid arthritis, Ulcerative colitis, Polyarticular course juvenile idiopathic arthritis.
At a glance
| Generic name | Tofacitinib tablet |
|---|---|
| Also known as | Xeljanz |
| Sponsor | Shanghai Zhongshan Hospital |
| Drug class | JAK inhibitor |
| Target | JAK1, JAK3 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Tofacitinib is a JAK inhibitor that blocks the JAK-STAT signaling pathway, which is critical for the production of pro-inflammatory cytokines like interferon-gamma, interleukin-2, and tumor necrosis factor-alpha. By inhibiting JAK1 and JAK3 preferentially, it reduces T-cell proliferation and activation, thereby suppressing the inflammatory response in autoimmune and inflammatory conditions.
Approved indications
- Rheumatoid arthritis
- Ulcerative colitis
- Polyarticular course juvenile idiopathic arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
Common side effects
- Upper respiratory tract infection
- Diarrhea
- Headache
- Elevated cholesterol
- Increased creatinine
- Herpes zoster reactivation
Key clinical trials
- Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease (PHASE2)
- Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications (PHASE1, PHASE2)
- Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis (PHASE2, PHASE3)
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (PHASE3)
- A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) (PHASE4)
- Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis
- A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis (PHASE2)
- Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo. (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |